CAJ | 학술논문

目的：探讨补肾活血颗粒对帕金森病模型大鼠黑质纹状体中B淋巴细胞瘤-2蛋白(B-cell lymphoma-2, bcl-2)、bax表达的影响。方法33只雄性SD大鼠随机分为生理盐水正常组、6-羟基多巴胺模型组和补肾活血颗粒治疗组,应用免疫组织化学染色技术观察大鼠黑质纹状体中bcl-2、bax表达的变化情况。结果模型组bcl-2在黑质和纹状体的细胞阳性表达率增殖指数( pro-liferation index,PI)分别为0．43±0．022、1．14±0．057,均低于正常组(均P<0．01)和治疗组(均P<0．01)。模型组bax在黑质和纹状体的PI值分别为2．07±0．104、2．86±0．143,均高于正常组(均P<0．01)和治疗组(均P<0．01)。结论补肾活血颗粒治疗帕金森病的疗效机制可能与上调帕金森病大鼠黑质纹状体系统bcl-2蛋白表达及下调bax蛋白表达有关。
목적：탐토보신활혈과립대파금삼병모형대서흑질문상체중B림파세포류-2단백(B-cell lymphoma-2, bcl-2)、bax표체적영향。방법33지웅성SD대서수궤분위생리염수정상조、6-간기다파알모형조화보신활혈과립치료조,응용면역조직화학염색기술관찰대서흑질문상체중bcl-2、bax표체적변화정황。결과모형조bcl-2재흑질화문상체적세포양성표체솔증식지수( pro-liferation index,PI)분별위0．43±0．022、1．14±0．057,균저우정상조(균P<0．01)화치료조(균P<0．01)。모형조bax재흑질화문상체적PI치분별위2．07±0．104、2．86±0．143,균고우정상조(균P<0．01)화치료조(균P<0．01)。결론보신활혈과립치료파금삼병적료효궤제가능여상조파금삼병대서흑질문상체계통bcl-2단백표체급하조bax단백표체유관。
Objective To observe the effects of Bushen Huoxue Granule( BSHXG) on the expres-sions of B-cell lymphoma-2(bcl-2) and bax in substantia nigra and striatum in rats model with Parkinson’s disease (PD). Methods Thirty-three male SD rats were randomly divided into 6-OHDA-induced PD model group, BSHXG treatment group and normal control group. Changes in the expressions of bcl-2 and bax in substantia nigra and striatum in rats were observed by means of immunohistochemical staining. Re-sults bcl-2’s proliferation indexes of positive expression rates of the cells in the substantia nigra of the PD model group and the striatum of the PD model group were respectively 0. 43 ± 0. 022,1. 14 ± 0. 057, both lower than the normal group (both P<0. 01) and treatment group (both P<0. 01) while bax’s PI in the substantia nigra of the PD model group and the striatum of the PD model group were respectively 2. 07 ± 0. 104、2. 86 ± 0. 143, both higher than the normal group (both P<0. 01) and treatment group (both P<0. 01). Conclusion The therapeutic effect of BSHXG on PD may be associated with up regulating the expression of bcl-2 protein and down regulating the expression of bax protein in substantia nigra and stria-tum in rats with Parkinson’s disease.